Accessibility
Language
The Inkjet-bioAM project is based on the premise that the digitalization of the production of medical products and pharmaceuticals is essential to improve patient care and the well-being of EU citizens, as well as to ensure the sustainability of the healthcare system. The aim of the project is to integrate inkjet printing technology into the value chain for the production of medical and pharmaceutical products. To this end, three specific objectives have been defined.
Objective 1: Bridge the gap between supply and demand for the adoption of inkjet technology in the biomedical sector by removing the bottlenecks that hinder the entry of inkjet technology into the biomedical sector (lack of biocompatible inkjet inks, need for further optimization of the multi-material inkjet printing process and need for GMP-compliant inkjet printers).
Objective 2: Demonstration, upscaling and interregional investment in pilot lines, with the implementation of 3 pilot lines based on inkjet printing technology for the production of medical devices and pharmaceuticals.
- Pilot line 1: Inkjet printing for the functionalization of bioscaffolds
- Pilot line 2: Inkjet printing for the functionalization of biosensors
- Pilot line 3: Inkjet printing for the personalization of pharmaceutical products.
Objective 3: Expansion of the EU ecosystem for inkjet printing in the biomedical sector. The consortium consists of 15 partners from 8 different regions in Europe, two of which belong to the less developed regions, with the common S3 thematic platform for industrial modernization. In addition, the participating regions have complementary smart specialization areas aligned with the theme of the current project: Health, Industrialization and Smart Manufacturing.
